Literature DB >> 8982111

Increased Fas antigen on T cells in multiple sclerosis.

H Ichikawa1, K Ota, M Iwata.   

Abstract

Programmed cell death of antigen specific T cells (apoptosis) may be an important process in the pathogenesis of autoimmune diseases such as multiple sclerosis (MS). Fas antigen was recognized as an apoptosis-related antigen. To investigate Fas antigen in multiple sclerosis (MS), we measured the expression rate of Fas antigen and activation markers on T cells in peripheral blood (PB) of 19 MS patients, 18 controls and in cerebrospinal fluid (CSF) of nine MS patients by flow cytometry. The positive rate of Fas antigen in MS patients was higher than that of healthy controls in PB. In patients with MS, the expression rates of Fas antigen and activation markers were higher in CSF than in PB. The above findings suggest that there is acceleration or impairment of apoptosis on activated T cells in MS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982111     DOI: 10.1016/s0165-5728(96)00149-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

2.  Involvement of IFN-γ and perforin, but not Fas/FasL interactions in regulatory T cell-mediated suppression of experimental autoimmune encephalomyelitis.

Authors:  Tara Beeston; Trevor R F Smith; Igor Maricic; Xiaolei Tang; Vipin Kumar
Journal:  J Neuroimmunol       Date:  2010-08-12       Impact factor: 3.478

3.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

4.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

Review 5.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

6.  A protein critical for a Theiler's virus-induced immune system-mediated demyelinating disease has a cell type-specific antiapoptotic effect and a key role in virus persistence.

Authors:  G D Ghadge; L Ma; S Sato; J Kim; R P Roos
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.

Authors:  Dan M Waid; Teri Schreiner; Gisela Vaitaitis; Jessica R Carter; John R Corboy; David H Wagner
Journal:  J Neuroimmunol       Date:  2014-03-15       Impact factor: 3.478

8.  A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation.

Authors:  Soraya Maria Menezes; Fabio E Leal; Tim Dierckx; Ricardo Khouri; Daniele Decanine; Gilvaneia Silva-Santos; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Douglas F Nixon; Jurgen Vercauteren; David Brassat; Roland Liblau; Anne Mieke Vandamme; Bernardo Galvão-Castro; Johan Van Weyenbergh
Journal:  Front Immunol       Date:  2017-02-14       Impact factor: 7.561

9.  The IL-27/IL-27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients.

Authors:  Marie-Laure Clénet; Cyril Laurent; Florent Lemaitre; Negar Farzam-Kia; Olivier Tastet; Odile Devergne; Boaz Lahav; Marc Girard; Pierre Duquette; Alexandre Prat; Catherine Larochelle; Nathalie Arbour
Journal:  Clin Transl Immunology       Date:  2021-03-05

10.  Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis.

Authors:  K A Sabelko-Downes; A H Cross; J H Russell
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.